Femara (Letrozole) for Fertility: FDA Approval History, Label, and What Every Woman Should Know

Why Letrozole Is Used for Fertility When the FDA Never Approved It for That

Letrozole is the most commonly prescribed ovulation-induction drug in the United States today, despite carrying no FDA fertility indication. That gap between regulatory status and clinical reality confuses many women, and for good reason. Understanding why that gap exists tells you a great deal about how drug regulation works, and about where the actual evidence sits.

The FDA approved letrozole in December 1997 as an aromatase inhibitor for hormone-receptor-positive breast cancer in postmenopausal women. Novartis developed it under the brand name Femara for that purpose entirely. The fertility application came later, from clinicians who noticed that aromatase inhibition sharply drops estrogen levels, which causes the pituitary to release more follicle-stimulating hormone (FSH), triggering ovulation.

How Off-Label Prescribing Works in Women's Health

Off-label prescribing is legal and common. The FDA regulates drug approval, not medical practice. A physician may prescribe any approved drug for any condition she judges to be clinically appropriate. ACOG estimates that roughly one in five prescriptions written by obstetrician-gynecologists are off-label. In reproductive endocrinology, that proportion is higher still, because clinical evidence and guideline recommendations frequently outpace the commercial incentive for manufacturers to fund a supplemental New Drug Application (sNDA).

Novartis never pursued FDA approval for letrozole as a fertility drug, and generic manufacturers have even less financial reason to do so. The drug has been off patent since 2011. Regulatory approval costs tens of millions of dollars. The economics simply do not favor it.

The 2005 Controversy That Shaped the Label

In 2005, Novartis added language to the Femara label warning against use in premenopausal women and specifically in women seeking pregnancy. That addition followed a conference abstract presented by Biljan et al. That reported a higher rate of congenital cardiac and skeletal anomalies in infants conceived after letrozole compared to clomiphene. The abstract was never published as a peer-reviewed paper. Subsequent studies did not replicate the signal.

The 2005 Femara label update explicitly contraindicated use in premenopausal women, not because of confirmed teratogenicity in well-designed trials, but because the drug is a potent estrogen suppressor and its approved population was postmenopausal. The label language was written for a cancer indication, not fertility. Applying it directly to off-label fertility use requires clinical nuance that the label itself does not provide.

What the Femara Label Actually Says (and What It Does Not)

The current FDA-approved label for Femara addresses a postmenopausal oncology population exclusively. Reading the label through a fertility lens requires knowing what it covers and what it was never designed to address.

Approved Indications on the Label

The label lists three breast-cancer indications for postmenopausal women:

• Adjuvant treatment of hormone-receptor-positive early breast cancer
• Extended adjuvant treatment after five years of tamoxifen
• First-line or second-line treatment of hormone-receptor-positive advanced or metastatic breast cancer

Fertility, ovulation induction, and ovarian stimulation do not appear anywhere in the approved indications section.

Contraindications and Warnings Relevant to Reproductive-Age Women

The label carries a contraindication in women who are or may become pregnant, with a warning that letrozole can cause fetal harm. This statement was written in the context of a postmenopausal breast cancer drug whose primary mechanism lowers estrogen, a hormone required for normal fetal development. The label also notes potential embryotoxicity and fetotoxicity in animal studies.

What the label does not contain is any efficacy or dosing data for premenopausal women using letrozole for ovulation induction. Clinicians who prescribe letrozole for fertility are relying on the peer-reviewed literature and specialty society guidelines, not on the FDA label. That distinction matters, and you deserve to know it.

Dosing in the Label vs Dosing in Fertility Practice

The approved oncology dose is 2.5 mg once daily continuously. Fertility dosing is structurally different: short-course, typically 2.5 mg to 7.5 mg daily for five days (cycle days 3 to 7 or days 5 to 9). This pulsed regimen was developed specifically to trigger a time-limited FSH surge that recruits one or two follicles without prolonged estrogen suppression. The label provides zero guidance on this regimen because it was designed for a completely different pharmacological objective.

The Clinical Evidence That Made Letrozole the Standard

The off-label status of letrozole for fertility does not mean the evidence is weak. The opposite is true: the evidence base is stronger than that for many FDA-approved fertility drugs.

The Legro 2014 NEJM Trial: The Study That Changed Practice

The single most important trial is the Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) study, published in the New England Journal of Medicine in 2014. Legro and colleagues randomized 750 women with PCOS to letrozole 2.5 mg to 7.5 mg (stepped up by cycle) or clomiphene 50 mg to 150 mg for up to five treatment cycles.

The results were unambiguous:

• Live birth rate: letrozole 27.5% vs clomiphene 19.1% (p = 0.007)
• Ovulation rate per cycle: letrozole 61.7% vs clomiphene 48.3%
• Twin rate: letrozole 3.4% vs clomiphene 7.4%

The twin-rate difference matters for women. Multiple gestation raises the risk of preterm birth, low birth weight, gestational hypertension, and cesarean delivery. Letrozole's lower multiple-pregnancy rate is a direct clinical benefit, not a footnote.

The PPCOS II trial also found that cumulative ovulation rates favored letrozole across all BMI categories, which is especially relevant because PCOS-related infertility disproportionately affects women with higher BMIs, a population in which clomiphene is known to underperform.

ASRM and ACOG Guideline Positions

The American Society for Reproductive Medicine published a 2023 evidence-based guideline stating that letrozole is the first-line ovulation-induction agent for women with PCOS who are trying to conceive, acknowledging the off-label status explicitly and stating that the evidence is sufficient to support clinical use.

ACOG similarly endorses letrozole for ovulation induction in anovulatory infertility. The guideline text reads: "Letrozole has been shown to result in higher live birth rates than clomiphene citrate in women with PCOS and is considered by many reproductive endocrinologists to be the preferred agent for ovulation induction."

These guideline endorsements carry more clinical weight for daily practice than the absence of an FDA fertility indication, because guidelines synthesize the totality of trial evidence whereas FDA approval reflects a manufacturer-filed dossier.

Evidence in Non-PCOS Populations

Data for letrozole in unexplained infertility is less definitive than the PCOS data, but still supportive. The AMIGOS trial (Legro et al., NEJM 2015) randomized 900 couples with unexplained infertility to letrozole, clomiphene, or gonadotropins combined with intrauterine insemination (IUI). Letrozole did not outperform clomiphene for live birth in that population (19.4% vs 23.3%), though it had a lower multiple-pregnancy rate. This matters: the strong case for letrozole is specifically in ovulatory dysfunction, particularly PCOS. In unexplained infertility, clomiphene remains a reasonable option.

WomanRx Life-Stage Framework for Letrozole Fertility Use:

| Life Stage | Letrozole Role | Key Consideration | |---|---|---| | Reproductive years, PCOS | First-line ovulation induction | Off-label; superior live birth vs clomiphene (PPCOS II) | | Reproductive years, unexplained infertility | Second-line or equivalent to clomiphene | AMIGOS trial; no clear superiority | | Reproductive years, endometriosis | Used adjunctively; evidence limited | Extrapolated from general ovulation induction data | | Trying to conceive after breast cancer | Studied in IBCSG SOFT/TEXT context; highly specialist decision | Requires oncology and REI collaboration | | Perimenopause | Not indicated for fertility | Diminished ovarian reserve changes risk-benefit entirely | | Postmenopause | Breast cancer indication only | No fertility application |

Sex-Specific Physiology: Why Letrozole Works Differently in Premenopausal Women

Letrozole blocks aromatase, the enzyme that converts androgens (testosterone and androstenedione) into estrogens. In a postmenopausal woman with breast cancer, that suppression is continuous and therapeutic. In a premenopausal woman using letrozole for ovulation induction, the same mechanism operates but in a hormonal environment that is fundamentally different.

The FSH Rebound Mechanism

In premenopausal women, estrogen exerts negative feedback on the hypothalamus and pituitary. When letrozole drops estrogen acutely over five days, the pituitary interprets this as a signal to release more FSH. That FSH surge stimulates follicular growth. Once letrozole is cleared (half-life approximately 48 hours), estrogen rises from the growing follicle, the natural LH surge occurs, and ovulation follows. The short-course dosing strategy was designed precisely around this half-life, ensuring the drug clears before implantation could be affected.

PCOS-Specific Physiology

Women with PCOS already have elevated androgen levels. Clomiphene, which works by blocking estrogen receptors, can deplete cervical mucus and thin the endometrial lining over repeated cycles because of its anti-estrogenic effects on peripheral tissue. Letrozole does not bind estrogen receptors. It only inhibits aromatase transiently. Estrogen levels recover fully after the drug clears, preserving endometrial thickness and cervical mucus quality. Endometrial thickness on the day of trigger is consistently higher with letrozole than clomiphene in head-to-head studies, which may partially explain the superior implantation and live birth rates.

Women with PCOS also have higher baseline androgen levels. Letrozole's aromatase inhibition paradoxically increases intraovarian androgen transiently, which may enhance FSH receptor sensitivity and promote follicular growth. This is a mechanism specific to the PCOS ovarian environment and does not apply in the same way to normo-androgenic women.

Cycle Monitoring Considerations

Because letrozole can occasionally produce more than one mature follicle, transvaginal ultrasound monitoring is recommended, particularly in the first treatment cycle and when doses exceed 5 mg. The goal is to identify women at risk of multiple gestation before ovulation is triggered. If three or more mature follicles (>14 mm) are present, most reproductive endocrinologists recommend canceling the cycle or converting to IVF egg retrieval.

Pregnancy and Lactation Safety: What You Must Know Before Starting Letrozole

Letrozole is a teratogen by label classification, and you should not take it if you are already pregnant. Full stop. Here is what the evidence and labeling say more specifically.

Pregnancy Category and Human Data

The FDA no longer uses the A-B-C-D-X letter categories for drugs approved after 2015, but Femara (approved 1997) retains its labeling under the older system. The label classifies letrozole as Pregnancy Category D/X depending on context: the drug can cause fetal harm, and use in pregnant women is contraindicated for the breast cancer indication.

The critical question for fertility patients is different: what is the risk to a fetus conceived after a letrozole cycle, where the drug was taken before confirmed pregnancy and had already been cleared?

The 2014 PPCOS II trial tracked congenital anomalies in all live births. Major congenital anomaly rates were 1.8% in the letrozole group and 1.4% in the clomiphene group, a difference that was not statistically significant. A 2014 meta-analysis in Fertility and Sterility found no significant increase in congenital malformations in infants conceived after letrozole ovulation induction compared to spontaneous conception or clomiphene cycles.

The 2005 Biljan conference-abstract signal, which prompted the label warning, has not been replicated in peer-reviewed studies. The current clinical consensus, reflected in ASRM guidelines, is that letrozole used for short-course ovulation induction, and stopped before confirmed pregnancy, does not carry a proven teratogenic risk to the fetus.

What This Means in Practice

You should:

1. Take letrozole only on the prescribed cycle days (typically days 3 to 7).
2. Confirm ovulation via ultrasound or LH testing.
3. Stop letrozole completely once ovulation has occurred.
4. Take a pregnancy test if your period is late, and inform your provider immediately.
5. Never take letrozole if you already have a positive pregnancy test.

The drug clears within approximately four to five half-lives (roughly 10 days) after the last dose. By the time implantation occurs (approximately seven to ten days after ovulation), letrozole is no longer detectable in most women.

Lactation

Letrozole is contraindicated during breastfeeding for two reasons. Estrogen is required for milk production (lactogenesis II and galactopoiesis). Letrozole suppresses estrogen. Taking letrozole while breastfeeding may reduce or stop milk supply. Separately, letrozole transfer into breast milk has not been well studied in humans, and the theoretical risk of estrogen suppression in a nursing infant makes use incompatible with breastfeeding. If you are postpartum and breastfeeding, letrozole for ovulation induction should not be started until you have fully weaned.

Contraception Requirement

This may sound counterintuitive for a fertility drug, but women using letrozole for ovulation induction who do not wish to conceive in a given cycle need a barrier method. Letrozole can trigger ovulation unpredictably, including in women who have been anovulatory. If you are in an IUI or timed intercourse cycle and the cycle is canceled due to too many follicles, use condoms or abstain for that cycle.

Who This Is Right for, and Who Should Think Carefully

Letrozole for ovulation induction fits a specific clinical profile. It is not the right drug for every woman who wants to conceive.

Most Likely to Benefit

• Women with PCOS and anovulatory infertility who have not conceived after three to six months of timed intercourse
• Women with clomiphene-resistant PCOS (defined as failure to ovulate on 150 mg clomiphene)
• Women with unexplained infertility proceeding to IUI, where lower multiple-pregnancy risk is a priority
• Women in whom clomiphene caused significant endometrial thinning or cervical mucus drying in prior cycles

Requires Careful Consideration

• Women with diminished ovarian reserve (AMH <1.0 ng/mL or antral follicle count <6): letrozole may not generate an adequate follicular response; gonadotropin injections may be more appropriate
• Women over 38: time is a clinical factor; proceeding directly to IVF should be discussed early
• Women with a personal history of hormone-receptor-positive breast cancer: letrozole use for fertility in this setting requires joint decision-making with oncology and reproductive endocrinology; the evidence base is small
• Women with unexplained infertility and no prior treatments: clomiphene or gonadotropins with IUI may be equally appropriate and are sometimes preferred by insurers for step-therapy requirements

Not Appropriate

• Women who are pregnant
• Women who are breastfeeding
• Women in perimenopause or postmenopause using letrozole for fertility (letrozole cannot restore fertility in these stages; any letrozole use in this group is for the breast cancer indication only)

Monitoring, Side Effects, and What the Evidence Says About Ovarian Cancer Risk

Common Side Effects in Fertility Cycles

Short-course letrozole for ovulation induction carries a different side-effect profile than chronic letrozole for breast cancer. In fertility cycles, the most commonly reported effects include:

• Hot flashes during the five-day course (transient; driven by acute estrogen drop)
• Mild fatigue
• Headache
• Occasional spotting between cycles

These effects resolve once the drug course is complete and estrogen recovers. They are generally mild. In the PPCOS II trial, discontinuation due to side effects was uncommon in both arms.

Ovarian Cancer Risk: What the Data Show

A 2013 concern about ovulation-induction drugs and ovarian cancer risk prompted the FDA to require label updates for clomiphene. Letrozole was examined in a 2015 cohort study in Fertility and Sterility and in a 2023 population-based Danish cohort involving over 100,000 women treated for infertility. Neither study found a statistically significant association between letrozole use and ovarian cancer risk after adjusting for underlying infertility diagnosis. The underlying infertility itself (particularly PCOS and endometriosis) may carry an independent association with ovarian pathology, which makes attributing risk to the drug difficult.

The current ASRM position is that the available evidence does not support a causal link between letrozole ovulation induction and ovarian cancer, though long-term surveillance data are still accumulating.

Ovarian Hyperstimulation Syndrome (OHSS) Risk

OHSS is substantially less common with letrozole than with gonadotropin injections, and appears to be lower than with clomiphene in women with PCOS. Because letrozole works through a ceiling effect (the FSH rise is self-limited by the drug's clearance and estrogen recovery), the ovarian response is generally more controlled. Severe OHSS with letrozole-only cycles is rare. Women with very high antral follicle counts (>20) should still be monitored carefully, because even moderate FSH stimulation can recruit many follicles in that setting.

The Evidence Gap: What We Do Not Know

Women have been systematically underrepresented in early drug trials, and letrozole's fertility evidence base, though stronger than for many drugs, has gaps worth naming.

The majority of ovulation-induction trials focus on PCOS, which means women with ovulatory infertility due to other causes (hypothalamic amenorrhea, premature ovarian insufficiency treated with hormone replacement, or idiopathic causes) have far less direct evidence for letrozole. Extrapolation from the PCOS data is common in clinical practice but is extrapolation, not direct evidence.

Long-term follow-up data on children conceived after letrozole ovulation induction remain limited. The PPCOS II trial followed newborns to discharge but did not track developmental outcomes. Larger registry studies, including the SART CORS database, are accumulating real-world outcomes data but have not yet published long-term pediatric follow-up for letrozole-conceived pregnancies at scale.

The racial and ethnic diversity in letrozole fertility trials is limited. The PPCOS II trial enrolled women from fertility clinics across the United States, but was not powered to detect differential efficacy or safety by race or ethnicity. Black women have a higher prevalence of PCOS-related anovulatory infertility and face documented disparities in access to reproductive endocrinology care. Whether letrozole efficacy differs by genetic ancestry or by androgen-receptor polymorphisms has not been systematically studied.